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ABSTRACT 
Artemisinins-based combination therapies (ACTs) are being recommended against uncomplicated malaria in endemic areas 
of Africa. However, in these areas data on their long term usefulness is limited. It has been demonstrated that ACTs 
resistance may be due to single nucleotide polymorphisms (SNPs) in the chemotherapeutic target, the SERCA-type ATPase 
protein (PfATPase6). This study analyzed PfATPase6 mutations in asymptomatic infections from samples collected from 
Mbita, a malaria endemic region in Kenya. Mutations in A623E and S769N residues were screened with gene specific 
primers followed by sequencing. The study demonstrates that there is no mutation in Mbita, Kenya because neither A623E 
nor S769N PfATPase6 mutations were detected. Resurgence of infections in this area could be due to re-infections and not 
drug failure. The study recommends that other sites be assessed for PfATPase 6 mutations to verify the long-term 
usefulness of ACT and monitor any emergency of resistance.  
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INTRODUCTION 
Resistance to anti-malarials is a major drawback in 
effective management and control of malaria in sub-
Saharan Africa. Plasmodium falciparum has 
developed high levels of resistance to the available, 
cheap and safe drugs such as, chloroquine (CQ) and 
sulfadoxine pyrimethamine (SP) [1, 2], and this has 
led to the recommendation of artemisinins-based 
combination therapy (ACT) as a first-line drug in 
various sub-Saharan countries [2]. Following 
increased SP resistance in Kenya, the country 
revised its malaria treatment policy to adopt 
artermether+lumefantrine [3, 4].  
 
The artemisinins compounds act by the haem-
catalysed intra-parasitic production of highly 
reactive carbon-centred free radicals [5, 6]. Certain 
haemo-globinopathies have been associated with 
reduced artemisinins activity, possibly because of 
reduced intra-erythrocytic availability of iron to 
catalyse opening of the peroxide bridge [6]. Recent 
study suggested that a sarco-endoplasmic reticulum 
Ca2+ ATPase (SERCA)-type protein encoded by a 
gene denoted PfATPase6 might be the major 
chemotherapeutic target of artemisinins drugs [7]. 
Artemisinins has been found to interact and 
selectively inhibit PfATPase6, the only SERCA-type 
Ca2+-ATPase6 in the P. falciparum genome [7, 8].  
Artemisinins have the broadest anti-malarial 
activity against parasites, from the ring stage to  
 
 
early schizonts, and cause the fastest decline in 
parasite numbers of all the anti-malarials. 
 
Their short half-lives limit the possibility of 
selection for resistance [6]. Heavy use of 
artemisinins in mono-therapy has been associated 
with selective pressure in parasites isolated from 
French Guyana and in in-vitro study in Senegal [9]. 
Recently, partial artemisinins resistant P. 
falciparum malaria has emerged on the Cambodia–
Thailand border. 
 
Exposure of the parasite population to artemisinins 
monotherapies in sub-therapeutic doses for over 30 
years, and the availability of substandard 
artemisinins, have probably been the main driving 
force in the selection of the resistant phenotype in 
the region [10]. Studies with murine malaria model 
demonstrated increased resistance to artemisinins 
[11].  
 
A subsequent in-vitro study in French Guyana 
showed that P. falciparum with elevated IC50 values 
for artemisinins shared specific point mutations at 
codon S769N of the ATPase6 locus. In addition, 
ATPase6 A623E and E431K mutations were also 
associated with reduced P. falciparum susceptibility 
to artemisinins [9]. 
 
Strong evidence shows that resistance to 
artemisinins may depend on SNPs in the drug's 





ATPase protein (PfATP6) but epidemiological 
evaluation of gene copy numbers in natural parasite 
populations has not been carried out [7]. Residues 
S769N, L263E, E431K and A623E are associated with 
resistance [9, 13]. The S769N mutation differs from 
the engineered L263E replacement, which abolished 
artemisinins inhibition of the PfATPase6 activity 
[13], while the residue S769N is located within the 
cytoplasmic N (nucleotide binding) domain close to 
a conserved hinge, which in other species is 
essential in the structural transitions crucial in the 
progress of the ATPase cycle, calcium binding and 
release [8].   
 
To date no relevant clinical resistance to 
artemisinins has been reported in Kenya. However, 
the long-term usefulness of ACT in endemic areas 
remains unclear [12]. Therefore, as ACT becomes 
widely used in sub-Saharan Africa, regular and 
comprehensive surveillance of resistance is of great 
importance.  Predicting the emergence and spread 
of resistance to current anti-malarials and newly 
introduced compounds is necessary for planning 
malaria control and instituting strategies that might 
delay the emergence of resistance.  
The present study analysed PfATPase6 mutations in 
asymptomatic infections from samples collected 
from Mbita, a malaria endemic region in Kenya. 
Mutations were screened at A623E and S769N 
residues. The study recommends that other sites be 
assessed for PfATPase 6 mutations to verify the 
long-term usefulness of ACT and monitor any 
emergency of resistance. 
 
MATERIALS AND METHODS 
STUDY SITE AND SAMPLE COLLECTION 
The study protocol was approved by the scientific 
steering committee and the ethical review 
committee of the Kenya Medical Research Institute 
(KEMRI), Nairobi, Kenya. Written and informed 
consent forms presented in native language and 
translated to the patients were obtained from the 
study participants. Blood samples were collected as 
dry blood spots on Whatman 3M filter papers from 
thirty patients presenting with asymptomatic 
malaria. The filters were air dried and packed in 
sealed plastic bags and stored at 4 oC until further 
analysis. 
 
DNA EXTRACTION AND AMPLIFICATION 
DNA from filter papers was extracted according to 
Warhust et al method, [14], with slight 
modifications. Briefly, 4mm2 piece of filter with 
blood spot was cut with a sterile scalpel blade and 
incubated in 0.5% saponins in 1× PBS overnight at 4 
oC. The brown solution was removed and replaced 
with 1× PBS and then incubated for 20 minutes. The 
solution was removed and 100µl of DNAse free 
water was added followed by 50µl of 20% Chelex. 
The tubes were placed into a heated block and 
vortexed every two minutes. This was repeated up 
to 5 times. The solution was centrifuged and the 
supernatant carefully separated. The supernatant 
contains DNA and 30 µl aliquots were taken into 
eppendorf tubes and stored at -20 oC for PCR 
analysis. 
 
The amplification of a 696 base pair fragment of the 
PfATPase6 gene was carried out on an MJ 
ThermocyclerTM using the following as forward and 
reverse primers;  
7F-AATCACCAAGGGGTATCAAC and  
8R-ACGTATACCAGCCATATGG,  
and these targeted a 1771–2467bp region (S769N 
and A623E) codons on PfATPase6 gene.  
 
Amplification was carried out in 30 µl reaction 
volumes which comprised of 3 µl of the template 
DNA, 30nM of each primer, 200 µM of dNTP mix 
and 0.3 units of Taq Polymerase. For each run, a 
positive control (molecular weight marker) and a 
negative control (all reagents minus DNA template) 
were included. The cycling profile consisted of 
initial denaturation at 94 oC for 3 minutes followed 
by 35 cycles at 94 oC for 1 minute, 55 oC for 1 minute 
and 72 oC for 1 minute and a final extension at 72 oC 
for 10 minutes. The PCR products were visualized 
on a 1.5 % ethidium bromide stained agarose gel in 
Tris Acetate EDTA (TAE) buffer. A PCR product of 
696bp was obtained as shown in figure 1.  
 
PCR PRODUCTS CLEANING AND 
SEQUENCING 
Five microlitres of each PCR product for the target 
fragment were cleaned using 2 µl of ExoSAP-IT® 
(Affymetrix, USA) following manufacturer’s 
instructions. This was carried out to check for 
mutations in the 623 and 769 residues.  Each 
product was sequenced using Bigdye® Technology 
using the 3700 X Genetic Analyzer (Applied 




The sequences were subjected to BLAST analysis 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi)  
to determine similarity with other sequences. The 
confirmed sequences were then analyzed using the 
SeqScape software version 2.5 (Applied Biosystems) 
that aligns and compares the sequences with the 
reference sequence.  
 
RESULTS 
DNA extracted from 30 samples collected from 
Mbita, was amplified with primers specific for 
PfATPase6 gene. A fragment of 696 base pair was 







Figure 1: PCR product of PfATPase gene from P. falciparum samples collected from Mbita. The amplicons are 
696 base pairs in samples labeled A up to P. Q and R represents negative control while, S and T is 1000 
molecular weight marker.  
 
The fragment was cleaned from the gel and 
sequenced to check for mutation in the residue 
S769N and A623S. It was found that there was no 
PfATPase6 S769N or A623E mutations in the 
samples sequenced. The sequences obtained were 
aligned with reference sequences for the purposes 
of comparison using BLAST, and then annotated in 
Genbank.  
 
The sequences were then aligned with reference 
sequences using SeqScape software version 2.5 
(Applied Biosystems). The software determines 
regions which have mutated in the corresponding 
sequence. It was found that the query and reference 
sequences matched perfectly, an indication that 
there were no mutations in the residues S769N and 
A623E. Sample alignment output from SeqScape 
software is shown in figure 2.  
 
 
Figure 2: The query comprises of the sequence sent to the database and the subject (sbjct) comprises of the 
reference sequence in the database.The green alignment shows the base pairs of codon 769 and 623 on both 
the query and the subject. It also shows the percentage similarities between the query and reference 
sequences.  
 
The sequences were submitted to GenBank for annotation and are available online as follows; GenBank: FJ384391, 
GenBank: FJ384392, GenBank: FJ384393, GenBank: FJ384394, GenBank: FJ384395, GenBank: FJ384396, GenBank: 
FJ384397, GenBank: FJ384398, GenBank: FJ384399, GenBank: FJ384400, GenBank: FJ384401, GenBank: FJ384402, 
GenBank: FJ384403, GenBank: FJ384404, GenBank: FJ384405, GenBank: FJ38406,  
GenBank: FJ384407, GenBank: FJ384408, GenBank: FJ384409, GenBank: FJ384410, GenBank: FJ384411, GenBank: 
FJ384412, GenBank: FJ384413, GenBank: FJ384414, GenBank: FJ384415, GenBank: FJ384416, GenBank: FJ384417, 








Malaria poses a risk to half of the world's population 
and more than a million people die of the disease 
each year. To this end, the disease has defied 
eradication in areas of intense transmission. Kenya 
adopted the artemisinins ACT in 2006 as the first line 
treatment for all uncomplicated malaria   
 
Artemisinin and its derivatives are the most potent 
and rapidly acting anti-malarials. Strong evidence has 
shown that resistance to artemisinins may depend on 
single nucleotide polymorphisms in the drug's 
putative chemotherapeutic target known as SERCA-
type ATPase protein [13]. It has been shown that 
residues S769N, L263E, E431K and A623E are 
associated with resistance to artemisinins [13]. 
Residue S769N is located within the cytoplasmic N 
(nucleotide binding) domain close to a conserved 
hinge, which in other species is essential for the 
structural transitions needed for the progress of the 
ATPase cycle and calcium binding and release [8].  
 
Epidemiological evaluation of gene copy numbers in 
natural parasite populations has not been 
conclusively carried out in malaria endemic parts of 
Kenya. This study found that there was neither S769N 
nor A623E PfATPase6 mutations in P. falciparum 
sequences sampled from Mbita, Kenya. A previous 
study by Bousema and colleagues reported that ACT 
administration in Mbita did not reduce the 
proportions of infected children [3]. It is clear to 
conclude from this study that the observed drug 
failure in the previous study [3] could have been due 
to re-infections and not resistance to ACT. This shows 
that the studied codons are in their wild type and the 
drug is effective in this area for the management of 
malaria. This study is consistent with findings from 
Kefas et al [13], that there were no S769N or A623E in 
1205 subjects studied in Tanzania [13].  
 
CONCLUSION 
Though the current study showed that there is no P. 
falciparum resistance to artemisinins because the 
screened codons were in their wild forms, there is a 
need to investigate factors that could aggravate 
infections despite use of ACTS.  Screening for other 
genes which could confer resistance to ACTs is 
urgently needed. Further screening of clinical samples 
from endemic areas in the region using L263E and 
E431K codons, and active surveillance of clinical 
response to ACT therapy will help establish the levels 
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